Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Emory University
City of Hope Medical Center
Emory University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute, Naples
Big Ten Cancer Research Consortium
Mayo Clinic
NRG Oncology
NRG Oncology
NRG Oncology
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Ohio State University Comprehensive Cancer Center
Wake Forest University Health Sciences
City of Hope Medical Center
Shandong Tumor Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Chinese PLA General Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Mayo Clinic
Mayo Clinic
University Health Network, Toronto
City of Hope Medical Center
University of Washington
Barbara Ann Karmanos Cancer Institute
Vanderbilt-Ingram Cancer Center
Emory University
Fudan University
Jonsson Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
AHS Cancer Control Alberta
Columbia University
Barbara Ann Karmanos Cancer Institute
Ohio State University Comprehensive Cancer Center
Fox Chase Cancer Center
THERABIONIC INC.
Gruppo Oncologico del Nord-Ovest
Fudan University
Aalborg University Hospital
Renmin Hospital of Wuhan University
Tongji Hospital
Tongji Hospital
Vanderbilt-Ingram Cancer Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS